Report Detail
Global Toripalimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4706221 |
- 09 June, 2026 |
- Global |
- 73 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Toripalimab market size was valued at US$ 329 million in 2025 and is forecast to a readjusted size of US$ 896 million by 2032 with a CAGR of 13.4% during review period.
Toripalimab is a humanized IgG4 monoclonal antibody and a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor. It works by binding to the PD-1 receptor on T cells, thereby blocking its interaction with PD-L1 and PD-L2. This mechanism relieves tumor-induced immunosuppression and restores and enhances the body’s anti-tumor immune response. Toripalimab is primarily used in the immunotherapy of various malignancies, such as melanoma, non-small cell lung cancer (NSCLC), and nasopharyngeal carcinoma. It has significant clinical value in the field of cancer immunotherapy.In 2025, global production of toripalimab reached approximately 1.2 million vials.
Toripalimab, as one of the first domestically developed and successfully internationalized PD-1 immune checkpoint inhibitors in China, holds an important position in the cancer immunotherapy market. With the continuous rise in global cancer incidence and the expanding clinical application of immunotherapy across multiple solid tumors, the PD-1 inhibitor market is maintaining rapid growth. Toripalimab has achieved relatively high market penetration in China, supported by a broad range of approved indications, the advancement of reimbursement coverage, and strong clinical performance in tumor types such as nasopharyngeal carcinoma. It is also gradually expanding into overseas markets, including Europe and the United States. From a competitive landscape perspective, the market is dominated by global blockbuster products such as pembrolizumab and nivolumab. However, domestic products demonstrate certain competitive advantages driven by pricing benefits and policy support. Looking ahead, with the approval of additional indications and the expansion of international commercialization, the market size of toripalimab is expected to continue growing, strengthening its position in the global PD-1 inhibitor landscape.
This report is a detailed and comprehensive analysis for global Toripalimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Toripalimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Toripalimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Toripalimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Toripalimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Shanghai Junshi Biosciences, Coherus BioSciences, Apotex, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Toripalimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monoclonal Antibody, mAb
Bispecific Antibody, BsAb
Market segment by Specification
80 mg / 4 mL
240 mg / 6 mL
Market segment by Sales Channels
Innovator
Generic
Market segment by Dosage Form
Injection
Sterile Powder for Injection
Market segment by Application
Melanoma
Non-Small Cell Lung Cancer
Nasopharyngeal Carcinoma, NPC
Esophageal Cancer
Hepatocellular Carcinoma, HCC
Urothelial Carcinoma
Others
Major players covered
Shanghai Junshi Biosciences
Coherus BioSciences
Apotex
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Toripalimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Toripalimab, with price, sales quantity, revenue, and global market share of Toripalimab from 2021 to 2026.
Chapter 3, the Toripalimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Toripalimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Toripalimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Toripalimab.
Chapter 14 and 15, to describe Toripalimab sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Toripalimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Monoclonal Antibody, mAb
- 1.3.3 Bispecific Antibody, BsAb
- 1.4 Market Analysis by Specification
- 1.4.1 Overview: Global Toripalimab Consumption Value by Specification: 2021 Versus 2025 Versus 2032
- 1.4.2 80 mg / 4 mL
- 1.4.3 240 mg / 6 mL
- 1.5 Market Analysis by Sales Channels
- 1.5.1 Overview: Global Toripalimab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.5.2 Innovator
- 1.5.3 Generic
- 1.6 Market Analysis by Dosage Form
- 1.6.1 Overview: Global Toripalimab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
- 1.6.2 Injection
- 1.6.3 Sterile Powder for Injection
- 1.7 Market Analysis by Application
- 1.7.1 Overview: Global Toripalimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.7.2 Melanoma
- 1.7.3 Non-Small Cell Lung Cancer
- 1.7.4 Nasopharyngeal Carcinoma, NPC
- 1.7.5 Esophageal Cancer
- 1.7.6 Hepatocellular Carcinoma, HCC
- 1.7.7 Urothelial Carcinoma
- 1.7.8 Others
- 1.8 Global Toripalimab Market Size & Forecast
- 1.8.1 Global Toripalimab Consumption Value (2021 & 2025 & 2032)
- 1.8.2 Global Toripalimab Sales Quantity (2021-2032)
- 1.8.3 Global Toripalimab Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Shanghai Junshi Biosciences
- 2.1.1 Shanghai Junshi Biosciences Details
- 2.1.2 Shanghai Junshi Biosciences Major Business
- 2.1.3 Shanghai Junshi Biosciences Toripalimab Product and Services
- 2.1.4 Shanghai Junshi Biosciences Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Shanghai Junshi Biosciences Recent Developments/Updates
- 2.2 Coherus BioSciences
- 2.2.1 Coherus BioSciences Details
- 2.2.2 Coherus BioSciences Major Business
- 2.2.3 Coherus BioSciences Toripalimab Product and Services
- 2.2.4 Coherus BioSciences Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Coherus BioSciences Recent Developments/Updates
- 2.3 Apotex
- 2.3.1 Apotex Details
- 2.3.2 Apotex Major Business
- 2.3.3 Apotex Toripalimab Product and Services
- 2.3.4 Apotex Toripalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Apotex Recent Developments/Updates
3 Competitive Environment: Toripalimab by Manufacturer
- 3.1 Global Toripalimab Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Toripalimab Revenue by Manufacturer (2021-2026)
- 3.3 Global Toripalimab Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Toripalimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Toripalimab Manufacturer Market Share in 2025
- 3.4.3 Top 6 Toripalimab Manufacturer Market Share in 2025
- 3.5 Toripalimab Market: Overall Company Footprint Analysis
- 3.5.1 Toripalimab Market: Region Footprint
- 3.5.2 Toripalimab Market: Company Product Type Footprint
- 3.5.3 Toripalimab Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Toripalimab Market Size by Region
- 4.1.1 Global Toripalimab Sales Quantity by Region (2021-2032)
- 4.1.2 Global Toripalimab Consumption Value by Region (2021-2032)
- 4.1.3 Global Toripalimab Average Price by Region (2021-2032)
- 4.2 North America Toripalimab Consumption Value (2021-2032)
- 4.3 Europe Toripalimab Consumption Value (2021-2032)
- 4.4 Asia-Pacific Toripalimab Consumption Value (2021-2032)
- 4.5 South America Toripalimab Consumption Value (2021-2032)
- 4.6 Middle East & Africa Toripalimab Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Toripalimab Sales Quantity by Type (2021-2032)
- 5.2 Global Toripalimab Consumption Value by Type (2021-2032)
- 5.3 Global Toripalimab Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Toripalimab Sales Quantity by Application (2021-2032)
- 6.2 Global Toripalimab Consumption Value by Application (2021-2032)
- 6.3 Global Toripalimab Average Price by Application (2021-2032)
7 North America
- 7.1 North America Toripalimab Sales Quantity by Type (2021-2032)
- 7.2 North America Toripalimab Sales Quantity by Application (2021-2032)
- 7.3 North America Toripalimab Market Size by Country
- 7.3.1 North America Toripalimab Sales Quantity by Country (2021-2032)
- 7.3.2 North America Toripalimab Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Toripalimab Sales Quantity by Type (2021-2032)
- 8.2 Europe Toripalimab Sales Quantity by Application (2021-2032)
- 8.3 Europe Toripalimab Market Size by Country
- 8.3.1 Europe Toripalimab Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Toripalimab Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Toripalimab Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Toripalimab Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Toripalimab Market Size by Region
- 9.3.1 Asia-Pacific Toripalimab Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Toripalimab Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Toripalimab Sales Quantity by Type (2021-2032)
- 10.2 South America Toripalimab Sales Quantity by Application (2021-2032)
- 10.3 South America Toripalimab Market Size by Country
- 10.3.1 South America Toripalimab Sales Quantity by Country (2021-2032)
- 10.3.2 South America Toripalimab Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Toripalimab Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Toripalimab Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Toripalimab Market Size by Country
- 11.3.1 Middle East & Africa Toripalimab Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Toripalimab Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Toripalimab Market Drivers
- 12.2 Toripalimab Market Restraints
- 12.3 Toripalimab Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Toripalimab and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Toripalimab
- 13.3 Toripalimab Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Toripalimab Typical Distributors
- 14.3 Toripalimab Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Toripalimab. Industry analysis & Market Report on Toripalimab is a syndicated market report, published as Global Toripalimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Toripalimab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
